08:00 , Oct 30, 2006 |  BC Week In Review  |  Company News

Cambrex, Lonza deal

CBM will sell its research bioproducts and microbial biopharma businesses to contract manufacturer LONN for $460 million in cash. The bioproducts business, which consists of research products, analytical systems and services, biotherapeutic media and sera...
00:52 , Oct 25, 2006 |  BC Extra  |  Top Story

Lonza to buy Cambrex units

CBM will sell its research bioproducts and microbial biopharma businesses to Lonza (SWX:LONN) for $460 million in cash. LONN said the bioproducts business will provide it with raw materials and testing services and allow it...